Specialty polymers for specialty applications. Apex Polymers tailor-makes high-performance ethylene copolymer resin based on individual customer requirements.

Developed revenue growth strategies for FMCG, biotech, and industrial material companies. Market analysis, IP review, and set product development milestones for early stage tech start-up.

Completed 9 projects- type: cost reduction, optimisation of capital, strategy, post-merger integration, corporate due diligence- industries: agriculture, mining, transport, energy, government, and entertainmentHighlights- Re-designed mine expansion plan to improve NPV by 80% while reducing capital expenditure by $13m- Identified $15m in savings by creating a merged procurement structure- Modeling of rail network resulted in a $7/tonne (23%) reduction in transport costs

Directed group strategy and business development resulting in the commercialisation of Genea Biocell's first product. Led a team of scientists in the development of disease-relevant cell types for use in drug discovery.

Neurodifferentiation of Huntington's disease-affected human embryonic stem cells to mature GABAergic neurons.

Thesis entitled "The role of excitatory amino acid transporter 2 in Alzheimer's disease" under the direction of Dr. Peter Dodd. The project involved delineating the mechanism for glutamatergic disruption in Alzheimer's disease using post-mortem human brain tissue. Emphasis was placed on splice variants of glutamate transporter, EAAT2, and the influence of APOE genotype on functional glutamate uptake.

Short term research project under the direction of Dr. Niels Danbolt. Contracted to clone and express three splice variants of GLT-1 in mammalian cell culture for the validation of antibodies.

Subcloning EGFP-labeled NMDA-NR1and GluR1 into Sindbis virus.